2-weeks placebo then gabapentin + 1-week placebo then gabapentin
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuralgia
Conditions
Neuralgia, Neuralgia, Postherpetic
Trial Timeline
Jul 1, 2004 → Jun 1, 2006
NCT ID
NCT00674687About 2-weeks placebo then gabapentin + 1-week placebo then gabapentin
2-weeks placebo then gabapentin + 1-week placebo then gabapentin is a pre-clinical stage product being developed by Pfizer for Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00674687. Target conditions include Neuralgia, Neuralgia, Postherpetic.
What happened to similar drugs?
8 of 18 similar drugs in Neuralgia were approved
Approved (8) Terminated (3) Active (8)
🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00674687 | Pre-clinical | Completed |
Competing Products
20 competing products in Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 26 |
| QUTENZA | Astellas Pharma | Approved | 43 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 35 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 2/3 | 38 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Galcanezumab | Eli Lilly | Approved | 43 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine | AbbVie | Phase 2 | 35 |
| MK-8291 + Placebo | Merck | Phase 1 | 29 |
| Etoricoxib + Placebo | Merck | Approved | 39 |
| Cetuximab + Placebo | Merck | Phase 2 | 35 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 27 |
| MK0759 | Merck | Phase 2 | 27 |
| MK0686 | Merck | Phase 2 | 27 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 29 |
| EMA401 + Placebo | Novartis | Phase 2 | 27 |
| pregabalin | Pfizer | Approved | 43 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 43 |